#United States #Friendswood #Castle Biosciences #DecisionDx-Melanoma #TissueCypher

Castle Biosciences Excels in Q1 2026 with Strong Revenue Growth

Castle Biosciences, Inc. (Nasdaq: CSTL), focused on enhancing health through pioneering tests, has recently unveiled its financial performance for the first quarter of 2026. In an impressive start to the year, the company reported revenue of $83.7 million, reflecting a strong trajectory despite a slight decrease compared to the same quarter in the previous year where revenues were $88.0 million. This performance has prompted Castle Biosciences to revise its revenue guidance for the entire year of 2026, raising the forecast from a range of $340-350 million to $345-355 million.

Operational Highlights

Castle's CEO, Derek Maetzold, praised the team's dedication, emphasizing how their efforts translated into tangible results. The company's core revenue generators — DecisionDx-Melanoma and TissueCypher — exhibited impressive year-over-year growth. Specifically, test volumes for DecisionDx-Melanoma surged 16%, while TissueCypher witnessed remarkable growth of 58%, with test reports reaching 10,021 and 11,745 respectively.

A critical factor in this growth was the expansion of evidence supporting the DecisionDx-Melanoma test, through a multicenter U.S. study demonstrating its predictive accuracy regarding sentinel lymph node positivity, which significantly aids in patient care decisions.

Financial Breakdown

The breakdown of Castle Biosciences' financials for Q1 2026 reveals a mix of successes and challenges. Notably:

• - Non-dermatologic test revenues rose to $42.6 million from $25.0 million year-over-year.
• - Gross margin improved to 73%, with adjusted gross margin at 76%. This contrasts sharply with the previous year's margins, hampered by a one-time expense adjustment.
• - While the net loss for Q1 2026 was recorded at $14.5 million (or $0.49 per share), this marked an improvement over the $25.8 million loss from the same quarter a year earlier. The adjusted EBITDA also saw a decline to $(5.1) million, down from $13.0 million in Q1 2025.

Indications from cash management show that Castle Biosciences currently holds approximately $261.7 million in cash, cash equivalents, and marketable securities, which supports ongoing operational activities and future investments in research and development.

Recent Developments and Future Outlook

Looking ahead, Castle Biosciences continues to build on its momentum. Recent data presentations at notable conferences showcased the efficacy of its tests in stratifying risks in skin cancer and Barrett's esophagus, further solidifying its market position. Initiatives supporting Skin Cancer Awareness Month are in place, aimed at improving patient education and early detection strategies, which not only enhance patient outcomes but also reinforce the company's community engagement philosophy.

In a conference call scheduled for today at 4:30 PM ET, Castle will discuss its Q1 results and offer further insights into its strategic direction. Investors and stakeholders are encouraged to engage and monitor the developments that continue to shape the company's future in the health diagnostics sector.

Castle Biosciences remains committed to its mission of developing cutting-edge diagnostics, ensuring informed patient care, and navigating the evolving landscape of healthcare requirements effectively. As the company propels into 2026, it remains a player to watch in the continually growing domain of medical diagnostics.